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New oral anticoagulants use
assessmentAbstract Background:Novel oral anticoagulants (NOACs) are considered to be at least as effective
and safe as warfarin with several advantages such as predictable pharmacokinetics, allowing for stan-
dardized dosingwithoutmonitoring, a lack of food interactions and fewer drug interactions; however,
their misuse could potentially result in patient harm.Objective: To evaluate the appropriate use of the
NOACs within a community teaching hospital. Setting: A community teaching hospital in the United
States.Method:Aretrospective chart review of patients thatwere prescribed dabigatran, rivaroxaban,
or apixaban at our institution fromOctober 2012 through November 2014 was conducted.Main out-
come measure: The primary objective was to determine the percentage of patients that were appropri-
ately prescribed NOACs. Secondary objectives were to determine the number of patients who were
inappropriately transitioned from warfarin or parenteral anticoagulants to a NOAC or vice versa,
the number of incidents when a NOAC was held or discontinued inappropriately before a procedure
and the number of bleeding or thrombotic events while taking a NOAC. Results: Of the 113 patients
receiving therapy with an NOAC, appropriate prescribing was observed in 79.7%. Dabigatran,
rivaroxaban, and apixaban were appropriately prescribed in 73.8%, 88.3%, and 85.8% of patients
respectively. Lack of renal dose-adjustment in patients with reduced renal function was themost com-
mon reason for inappropriate use (8.8%). Ten out of 38 patients (26%) were inappropriately transi-
tioned from/to other anticoagulants. Two out of six patients underwent a procedure without holding
NOACs as recommended prior to surgery. Of all patients receiving NOACs, a total of 3 bleeding inci-
dents were observed, one with each NOAC. Conclusion: The NOACs were appropriately prescribedh, Saudi
rmaceu-
2 S. Alghadeer, L. Hornsby
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tical Journal (2016), http://dx.doi.org/10.101for the majority of patients within our institution. Future efforts however should focus on ensuring
appropriate dose adjustments for renal impairment, procedures for transitioning between NOACs
and parenteral anticoagulants, and adequate withholding times for NOACs prior to surgery in order
to optimize the management of NOACs usage within our institution.
 2016 The Authors. Production and hosting by Elsevier B.V. on behalf of King Saud University. This is
an open access article under the CCBY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Until recently warfarin has been the sole oral anticoagulant for
the treatment and prevention of venous thromboembolism
(VTE) and stroke prevention in atrial fibrillation (AF). Despite
its efficacy, warfarin use is complicated by drug and food inter-
actions, a narrow therapeutic index, and required monitoring
to maintain an international normalized ratio (INR) within
the target therapeutic range (Coumadin, 2011). The novel oral
anticoagulants (NOACs), dabigatran, rivaroxaban, and apixa-
ban, are currently approved for the prevention of stroke or sys-
temic embolism in patients with nonvalvular AF and the
prevention and treatment of VTE (Pradaxa, 2013; Xarelto,
2014; Eliquis, 2014). Apixaban and rivaroxaban are approved
for VTE prevention post hip or knee replacement, and for
VTE treatment or prevention of recurrence (Xarelto, 2014;
Eliquis, 2014). Dabigatran is approved for treatment of VTE
in patients who have been treated with a parenteral anticoag-
ulant for 5–10 days, and to reduce the recurrence of VTE in
patients who have been previously treated (Pradaxa, 2013).
In general these agents are considered to be at least as effective
and safe as warfarin with several advantages such as pre-
dictable pharmacokinetics, allowing for standardized dosing
without monitoring, a lack of food interactions and fewer drug
interactions (Connolly et al., 2009; Schulman et al., 2009; Patel
et al., 2011; Turpie et al., 2011; Lopes et al., 2012; Bauersachs
et al., 2010; Buller et al., 2012; Agnelli et al., 2013; Lassen
et al., 2010a, 2010b).
Despite their advantages, these agents are nevertheless anti-
coagulants; therefore, their misuse could potentially result in
patient harm (NSW, 2014). Dosing of the NOACs is based
on indication and may require adjustments based on age,
weight, concurrent medications and/or renal function. At our
institution, initiation of the NOACs is performed by physi-
cians while pharmacists are responsible for daily monitoring
and usage. When initiating therapy, prescribers should take
into consideration the patient’s indication, renal function,
age, and body weight in addition to concomitant medications.
Changes in renal function and medication profile may necessi-
tate either a dose reduction or the discontinuation of these
agents during therapy. Furthermore, the transition between
warfarin or parenteral anticoagulants and NOACs should be
performed appropriately to avoid complications in addition
to avoiding inappropriate duplication of therapy.
The purpose of this study was to evaluate the appropriate
use of the NOACs (rivaroxaban, dabigatran, and apixaban)
within a community teaching hospital.
2. Methodology
A retrospective chart review of patients that were prescribed
dabigatran, rivaroxaban, or apixaban from October 2012S., Hornsby, L. Assessment of novel or
6/j.jsps.2016.02.002through November 2014 was conducted. Patients initiated on
a NOAC as well as those on a NOAC continued as a home
medication were included. Patients were excluded if there
was insufficient history or laboratory data to determine the
appropriateness of therapy or if they were seen in the emer-
gency department without an admission.
The primary objectives of the trial were to determine (1)
percentage of patients that were appropriate prescribed
NOACs (rivaroxaban, dabigatran, and apixaban), and (2)
the percentage of patients who received the correct dose of
each agent based on the specific indication, renal function,
age and/or body weight and concomitant medications. The
use of each NOAC was considered appropriate based on the
criteria listed in Appendix A.
The secondary objectives were to determine (1) the number
of patients who were inappropriately transitioned from war-
farin or parenteral anticoagulants to a NOAC or vice versa,
(2) the number of incidents when a NOAC was held or discon-
tinued inappropriately before a procedure, (3) the number of
orders for prothrombin time, aPTT, or INR obtained for the
purpose of assessing NOAC therapy, and (4) the number of
bleeding and thrombotic events in patients receiving a NOAC.
Data collected included the following: demographic data,
NOAC received, indication, dose, serum creatinine, any
known medications or concurrent disease states that may
affect the pharmacokinetics of NOACs and consideration for
dosing, coagulation laboratory results including INR values
for appropriate transition between NOACs and warfarin or
parenteral anticoagulants, any incidence of bleeding or throm-
boembolism, and any held, discontinued, or adjusted doses in
the NOAC during therapy.
3. Results
Of the 133 patients who received a NOAC from October
2012 through November 2014, a total of 113 patients were
included in the study. Twenty patients were excluded: fifteen
due to insufficient data available to evaluate the appropriate-
ness of use and five that were seen in the emergency depart-
ment without an admission. Sixty-five patients received
dabigatran, 34 rivaroxaban and 14 apixaban. The majority
received NOACs for stoke prevention in atrial fibrillation.
The mean age of patients was 70 years. For dabigatran, the
majority of patients were receiving therapy as a continuation
of therapy upon admission. For apixaban, more patients were
initiated on therapy during hospitalization and the number of
patients on rivaroxaban was more evenly split between the
continuation of home therapy and initiation during hospital-
ization. A small portion of patients received antiplatelet ther-
apy concurrently with NOACs for post-cardiac stent
placement, post-myocardial infraction, or cerebral vascular
accident (Table 1).al anticoagulant use within a community teaching hospitalq. Saudi Pharmaceu-
Figure 1 Appropriate use of combined novel oral anticoagulants
(NOACs).
Table 1 Baseline characteristics.
Dabigatran (n= 65) Rivaroxaban (n= 34) Apixaban (n= 14)
Mean ± SD age, yr 71 ± 11 70 ± 15 70 ± 14
Gender, n
Male 28 16 6
Female 37 18 8
Indication, n
Stroke prevention 64 21 9
VTE prophylaxis/treatment 1 13 5
Status of NOACs, n
Home medication 51 18 4
New start 14 16 10
Cancer, n 2 4 1
Concurrent use of antiplatelets, n
Aspirin 325 mg 3 0 0
Aspirin 81 mg 18 9 4
Clopidogrel 75 mg 1 1 1
VTE= venous thromboembolism, NOACs = novel oral anticoagulants.
Assessment of novel oral anticoagulant use 3Collectively the NOACs were prescribed appropriately in
79.7% (n= 90) of the patients (Fig. 1). Dabigatran, rivaroxa-
ban, and apixaban were prescribed appropriately in 73.8% (48
of 65), 88.3% (30 of 34), and 85.8% (12 of 14) respectively
(Fig. 2). Regarding inappropriate use, the dose of NOACs
was unadjusted (for specific indication, renal function, age
and/or weight) in 8.8% (n= 10) of patients collectively. All
cases were due to unadjusted doses in patients with renal
impairment and occurred in 9.2% (n= 6) of patients receiving
dabigatran, 8.8% (n= 3) of patients receiving rivaroxaban,
and 7.1% (n= 1) of patients receiving apixaban. NOAC drug
interactions without considering dose adjustment or medica-
tion discontinuation were identified in 3.5% (n= 4) of
patients. All drug interactions were identified in the dabigatran
group (6.2%). Concurrent administration of NOACs with
other anticoagulants was identified in 8% (n= 9) of patients
collectively; 10.8% (n= 7) in the dabigatran group, 2.9%
(n= 1) in the rivaroxaban group, and 7.1% (n= 1) in the
apixaban group. Most were given concurrently with enoxa-
parin (n= 6). Two patients were started on a NOAC while
receiving warfarin, and one patient received two NOACs
concurrently.
Thirty-eight patients were transitioned from a NOAC to
another anticoagulant or vice versa (Fig. 3). Ten of the 38
patients (26%) were inappropriately transitioned. The major-
ity of inappropriate transition was associated with the transi-
tion from enoxaparin to a NOAC (n= 7). The NOACs were
administered sooner than recommended after the discontinua-
tion of enoxaparin. Two were transitioned from a heparin
infusion and another from argatroban. In each situation,
administration of the NOAC was delayed for several hours
past the recommended time of transition. Of all patients
included in the study, six patients underwent a procedure while
they were on a NOAC, 3 patients on dabigatran and 3 on
rivaroxaban. In 2 of the dabigatran patients, surgery was initi-
ated prior to dabigatran being held for the recommended dura-
tion. None of the surgeries were urgent in nature. Of all
patients who received NOACs, a total of 3 bleeding incidentsPlease cite this article in press as: Alghadeer, S., Hornsby, L. Assessment of novel or
tical Journal (2016), http://dx.doi.org/10.1016/j.jsps.2016.02.002were observed: one bleeding incident with each NOAC. None
of these bleeding incidents appear to have been associated with
inappropriate use of the NOACs.
4. Discussion
The majority of patients were appropriately prescribed dabiga-
tran, rivaroxaban, and apixaban within our community teach-
ing hospital. The most common reason for inappropriate use
identified in this study was the absence of dose-adjustment in
patients with reduced renal function. There have been several
case reports of epistaxis, gastric hemorrhage, or other bleeding
events with dabigatran use in patients with impaired renal
function (Feinberg et al., 2014; Cano and Miyares, 2012;
Felows et al., 2013; Freshour et al., 2012; Maddry et al.,
2013; Schaeffer and Conway, 2013). Due to this concern and
from the results of our study, the addition of the NOACs to
the renal dose adjustment protocol at our institution will be
recommended. This will allow the pharmacist to automatically
adjust the dose of these agents based on the patient’s renal
function.al anticoagulant use within a community teaching hospitalq. Saudi Pharmaceu-
Figure 2 Appropriate use of individual novel oral anticoagulants (NOACs).
Figure 3 Secondary outcomes.
4 S. Alghadeer, L. HornsbyAlthough there are fewer drug interactions with the
NOACs, they are not obsolete. Interactions between the
NOACs and CYP3A4 inducers/inhibitors or P-glycoprotein
inducers/inhibitors have been reported. Cases resulting in
patient death, gastrointestinal bleeding, and pulmonary embo-
lism with rivaroxaban have been reported when given concur-
rently with rifampin, protease inhibitors and carbamazepine
respectively (Atlena et al., 2014; Lakatos et al., 2014;
Risselada et al., 2013). In our trial, concomitant administra-
tion of dabigatran with P-glycoprotein inducers was seen in
two cases with carbamazepine, one case with both phenytoin
and phenobarbital, and one case with phenytoin. In addition,
the NOACs are contraindicated in patients with prosthetic
heart valves due to an increased risk of thrombosis seen with
dabigatran in clinical trials. Despite this contraindication,
patients with mechanical valves have received dabigatran with
resultant valve thrombosis (Atar et al., 2013; Kuwauchi et al.,
2013; Price et al., 2012). None of the patients in our study had
a prosthetic heart valve. Coagulation tests such as prothrom-
bin time or activated partial thromboplastin time are often
obtained as an indicator of anticoagulation response or used
to guide dose adjustments with the NOACs; however, thisPlease cite this article in press as: Alghadeer, S., Hornsby, L. Assessment of novel or
tical Journal (2016), http://dx.doi.org/10.1016/j.jsps.2016.02.002practice is both inappropriate and costly (Deremer et al.,
2011). A total of 21 coagulation tests were ordered for our
patients in the study to assess therapy with the NOACs.
It is essential to understand the importance of discontinu-
ing these agents prior to surgery and when to do so. A resul-
tant patient death due to stroke has been reported in the
literature when dabigatran was ceased inappropriately prior
to a procedure (NSW, 2014). Although two patients in our
study underwent surgical procedures without the NOAC being
held for the recommendation duration, neither of these cases
resulted in bleeding. There have also been cases in which
patients received an additional anticoagulant such as warfarin
or heparin while receiving one of the NOACs, resulting in sig-
nificant bleeding. The concurrent administration of NOACs
with other anticoagulants was observed in 9 cases in our study,
most received enoxaparin along with the NOAC. None of
these cases resulted in a bleeding incidence during hospitaliza-
tion. The inappropriate transition between NOACs and other
anticoagulants may also put a patient at risk of bleeding and/
or thrombosis. We found that most patients being transitioned
were being transitioned from another anticoagulant to a
NOAC and there was a delay or advance in the administrational anticoagulant use within a community teaching hospitalq. Saudi Pharmaceu-
Assessment of novel oral anticoagulant use 5of the NOAC once the other anticoagulant was discontinued.
Therefore, developing a formalized guide for transitioning
between NOACs and other anticoagulants, and providing
additional education to physicians, nurses, and pharmacists
appear to be warranted.
There were several limitations to our study. This was a ret-
rospective review conducted at only one institution. All data
were collected from patients’ electronic medical records; there-
fore, there was the potential for missing information. Other
limitations include a limited follow-up period, and the major-
ity of patients were receiving dabigatran rather than the newer
NOACs, rivaroxaban and apixaban.
5. Conclusion
The novel oral anticoagulants were appropriately prescribed
for the vast majority of patients in our retrospective review
of patients receiving therapy at a community teaching hospital.
Efforts appear to be warranted to address areas such as dose
adjustment for renal impairment, transitioning between
NOACs and parenteral anticoagulants, and withholding
NOACs prior to surgery to optimize the management of
NOACs usage at our institution.
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Appendix A. Criteria of appropriate use of NOACs
Apixaban
The use of apixaban was considered appropriate if
(1) The dose was 5 mg BID for nonvalvular AF or 2.5 mg
BID if two of the following were present: age 80 years
or older, weight 60 kg or less, serum creatinine (SCr)
1.5 mg/dl or greater4
(2) The dose was 2.5 mg BID for VTE prevention post-hip or
knee replacement
(3) The dose was 10 mg BID for one week followed by 5 mg
BID for 6 months for patients diagnosed with DVT or
PE after August 21st, 2014
(4) The patient was not receiving a strong inducer of both
CYP3A4 and P-glycoprotein
(5) Dose reduction with concomitant use of strong inhibitors
of both CYP3A4 and P-glycoprotein
(6) Apixaban was discontinued 24 to 48 h in patients with
CrCl > 15 ml/min or 36–48 h in patients with
CrCl < 15 ml/min prior to a procedure
(7) The INR was <2 if switched from warfarin to apixaban
or apixaban was discontinued once an INR of 2–3 was
achieved in those being converted from apixaban to war-
farin or apixaban was discontinued once parenteral anti-
coagulation was initiated
Dabigatran
The use of Dabigatran was considered appropriate ifPlease cite this article in press as: Alghadeer, S., Hornsby, L. Assessment of novel or
tical Journal (2016), http://dx.doi.org/10.1016/j.jsps.2016.02.002(1) The dose was 150 mg BID for nonvalvular AF or 75 mg
BID if the CrCl was 15–30 ml/min2
(2) The dose was 150 mg BID for treatment of DVT or PE
after April 7th, 2014
(3) The patient was not on any strong inducers of both
CYP3A4 and P-glycoprotein
(4) Dose reduction was considered with concomitant use of
strong inhibitors of both CYP3A4 and P-glycoprotein
(5) Dabigatran was discontinued with CrCl < 15 ml/min in
AF or <30 ml/min in the treatment of VTE
(6) Dabigatran was discontinued 24–48 h with CrCl > 50 ml/
min or 48–96 h with CrCl 30–50 ml/min prior to a
procedure
(7) The INR was <2 if the patient was switched from war-
farin to dabigatran or dabigatran was discontinued once
an INR of 2–3 was achieved in those being converted from
dabigatran to warfarin or dabigatran was discontinued
once parenteral anticoagulation was initiated
Rivaroxaban
The use of rivaroxaban was considered appropriate if
(1) The dose was 20 mg daily with nonvalvular AF, or 15 mg
daily with a CrCl of 15–50 ml/min3
(2) The dose was 10 mg daily for VTE prevention post-hip or
knee replacement
(3) The dose was 15 mg BID for three weeks followed by
20 mg daily for the treatment of DVT or PE
(4) The patient was not on any strong inducers or inhibitors
of both CYP3A4 and P-glycoprotein
(5) Rivaroxaban was discontinued in patients with
CrCl < 15 ml/min in AF and <30 ml/min in VTE pre-
vention or treatment
(6) Rivaroxaban was discontinued 24–48 h with
CrCl > 15 ml/min or 36–48 h with CrCl < 15 ml/min
prior to a procedure
(7) The INR was <3 if the patient was switched from war-
farin to rivaroxaban or rivaroxaban was discontinued
once an INR of 2–3 was achieved in those being converted
from rivaroxaban to warfarin or rivaroxaban was discon-
tinued once parenteral anticoagulation was initiated
AF= atrial fibrillation; SCr = serum creatinine; VTE= venous
thromboembolism; DVT= deep vein thrombosis; PE = pul-
monary embolism; CrCl = creatinine clearance; INR= Interna-
tional normalized ratio.References
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